肿瘤预防与治疗2025，Vol.38Issue(4)：267-272,6.DOI:10.3969/j.issn.1674-0904.2025.04.003
免疫治疗推动局部晚期子宫颈癌治疗模式的变迁与发展
Immunotherapy Is Transforming the Treatment Paradigm for Locally Ad-vanced Cervical Cancer
摘要
Abstract
Locally advanced cervical cancer(LACC)has traditionally been treated with concurrent chemoradiotherapy(CCRT)as the standard approach,yet the 5-year survival rate remains at approximately 60％,highlighting an urgent need for breakthrough therapeutic strategies.Recent years have witnessed revolutionary advances in LACC treatment with the emergence of immune checkpoint inhibitors.The KEYNOTE-A18 trial demonstrated that adding pembrolizumab to CCRT sig-nificantly improved overall survival in high-risk LACC patients(HR=0.67),with a manageable safety profile,establishing this combination as the new standard of care for FIGO 2014 stage Ⅲ～ⅣA disease.This review critically examines the mecha-nisms of immunotherapy in LACC,key clinical trial findings,and future directions,aiming to provide multidimensional in-sights for clinical practice and research.关键词
局部晚期子宫颈癌/免疫治疗/免疫检查点抑制剂Key words
Locally advanced cervical cancer/Immunotherapy/Immune checkpoint inhibitors分类
临床医学引用本文复制引用
张国楠,向阳..免疫治疗推动局部晚期子宫颈癌治疗模式的变迁与发展[J].肿瘤预防与治疗,2025,38(4):267-272,6.基金项目
This study was supported by grants from Chinese Academy of Medical Sciences(No.2023-12M-C&T-B-037). 中国医学科学院临床与转化医学研究专项(编号:2023-12M-C&T-B-037) （No.2023-12M-C&T-B-037）
